WallStreetZenWallStreetZen

NASDAQ: HCM
Hutchmed Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for HCM

Based on 1 analyst offering 12 month price targets for Hutchmed Ltd.
Min Forecast
$19.00+16.56%
Avg Forecast
$19.00+16.56%
Max Forecast
$19.00+16.56%

Should I buy or sell HCM stock?

Based on 1 analyst offering ratings for Hutchmed Ltd.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HCM stock forecasts and price targets.

HCM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-01

1 of 1

Forecast return on equity

Is HCM forecast to generate an efficient return?
Company
261.38%
Industry
37.08%
Market
48.37%
HCM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HCM forecast to generate an efficient return on assets?
Company
153.42%
Industry
15.93%
HCM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HCM earnings per share forecast

What is HCM's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.33
Avg 2 year Forecast
$0.36
Avg 3 year Forecast
$0.86

HCM revenue forecast

What is HCM's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$689.6M+12.9%
Avg 2 year Forecast
$821.5M+34.49%
Avg 3 year Forecast
$1.0B+64.4%
HCM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HCM revenue growth forecast

How is HCM forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
17.56%
Industry
6.4%
Market
9.31%
HCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HCM vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
HCM$16.30$19.00+16.56%Hold
AMRX$8.83$9.00+1.93%Strong Buy
BHC$7.18$6.17-14.11%Sell
ALVO$11.01$18.00+63.49%Strong Buy
AMPH$48.64$66.00+35.69%Strong Buy
View Top Pharmaceutical Stocks

Hutchmed Stock Forecast FAQ

Is Hutchmed Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HCM) stock is to Hold HCM stock.

Out of 1 analyst, 0 (0%) are recommending HCM as a Strong Buy, 0 (0%) are recommending HCM as a Buy, 1 (100%) are recommending HCM as a Hold, 0 (0%) are recommending HCM as a Sell, and 0 (0%) are recommending HCM as a Strong Sell.

If you're new to stock investing, here's how to buy Hutchmed stock.

What is HCM's earnings growth forecast for 2024-2026?

(NASDAQ: HCM) Hutchmed's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 20.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.58%.

Hutchmed's earnings in 2024 is -$41,970,000.On average, 4 Wall Street analysts forecast HCM's earnings for 2024 to be -$289,727,107, with the lowest HCM earnings forecast at -$653,519,790, and the highest HCM earnings forecast at $60,995,180. On average, 4 Wall Street analysts forecast HCM's earnings for 2025 to be $313,689,499, with the lowest HCM earnings forecast at -$270,121,513, and the highest HCM earnings forecast at $906,214,109.

In 2026, HCM is forecast to generate $749,369,359 in earnings, with the lowest earnings forecast at $235,267,124 and the highest earnings forecast at $1,263,471,594.

What is HCM's revenue growth forecast for 2024-2026?

(NASDAQ: HCM) Hutchmed's forecast annual revenue growth rate of 17.56% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Hutchmed's revenue in 2024 is $610,806,000.On average, 3 Wall Street analysts forecast HCM's revenue for 2024 to be $600,914,060,984, with the lowest HCM revenue forecast at $533,002,027,127, and the highest HCM revenue forecast at $644,893,328,772. On average, 3 Wall Street analysts forecast HCM's revenue for 2025 to be $715,798,483,268, with the lowest HCM revenue forecast at $672,044,897,647, and the highest HCM revenue forecast at $741,178,577,832.

In 2026, HCM is forecast to generate $874,982,833,716 in revenue, with the lowest revenue forecast at $870,052,680,420 and the highest revenue forecast at $879,913,858,371.

What is HCM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: HCM) forecast ROA is 153.42%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.93%.

What is HCM's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HCM price target, the average HCM price target is $19.00, with the highest HCM stock price forecast at $19.00 and the lowest HCM stock price forecast at $19.00.

The Wall Street analyst predicted that Hutchmed's share price could reach $19.00 by Aug 1, 2025. The average Hutchmed stock price prediction forecasts a potential upside of 16.56% from the current HCM share price of $16.30.

What is HCM's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: HCM) Hutchmed's current Earnings Per Share (EPS) is -$0.25. On average, analysts forecast that HCM's EPS will be -$0.33 for 2024, with the lowest EPS forecast at -$0.75, and the highest EPS forecast at $0.07. On average, analysts forecast that HCM's EPS will be $0.36 for 2025, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at $1.04. In 2026, HCM's EPS is forecast to hit $0.86 (min: $0.27, max: $1.45).

What is HCM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: HCM) forecast ROE is 261.38%, which is considered strong.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.